TEZZURA Trademark

Trademark Overview

On Thursday, April 28, 2022, a trademark application was filed for TEZZURA with the United States Patent and Trademark Office. The USPTO has given the TEZZURA trademark a serial number of 97386851. The federal status of this trademark filing is REVIVED - AWAITING FURTHER ACTION as of Tuesday, October 7, 2025. This trademark is owned by TEVA PHARMACEUTICALS USA, Inc.. The TEZZURA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the prevention and treatment of autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders, dermatological diseases and disorders, musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, urogenital diseases and disorders, and urinary diseases and disorders, pharmaceutical preparations for use in the treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders; pharmaceutical preparations for use in smoking cessation; contraceptive preparations
tezzura

General Information

Serial Number97386851
Word MarkTEZZURA
Filing DateThursday, April 28, 2022
Status616 - REVIVED - AWAITING FURTHER ACTION
Status DateTuesday, October 7, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 4, 2023

Trademark Statements

Goods and ServicesPharmaceutical preparations for the prevention and treatment of autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders, dermatological diseases and disorders, musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, urogenital diseases and disorders, and urinary diseases and disorders, pharmaceutical preparations for use in the treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders; pharmaceutical preparations for use in smoking cessation; contraceptive preparations

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, May 3, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameTEVA PHARMACEUTICALS USA, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressParsippany, NJ 07054
Party NameTEVA PHARMACEUTICALS USA, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressParsippany, NJ 07054

Trademark Events

Event DateEvent Description
Tuesday, February 7, 2023ASSIGNED TO EXAMINER
Monday, May 2, 2022NEW APPLICATION ENTERED
Tuesday, May 3, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, July 7, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, July 7, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, July 7, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, February 22, 2023TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Tuesday, May 9, 2023TEAS VOLUNTARY AMENDMENT RECEIVED
Wednesday, February 15, 2023NON-FINAL ACTION WRITTEN
Wednesday, February 15, 2023NON-FINAL ACTION E-MAILED
Wednesday, February 15, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, February 22, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, February 22, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, February 22, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, May 30, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, May 9, 2023PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Wednesday, June 14, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, July 4, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, February 27, 2024SOU EXTENSION 1 GRANTED
Wednesday, February 28, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, July 4, 2023PUBLISHED FOR OPPOSITION
Tuesday, August 29, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, February 27, 2024SOU EXTENSION 1 FILED
Tuesday, February 27, 2024SOU TEAS EXTENSION RECEIVED
Monday, August 19, 2024SOU TEAS EXTENSION RECEIVED
Monday, August 19, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, August 19, 2024SOU EXTENSION 2 FILED
Wednesday, January 22, 2025SOU TEAS EXTENSION RECEIVED
Monday, September 29, 2025ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, August 19, 2024SOU EXTENSION 2 GRANTED
Wednesday, January 22, 2025SOU EXTENSION 3 FILED
Wednesday, January 22, 2025SOU EXTENSION 3 GRANTED
Monday, March 3, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, September 29, 2025ABANDONMENT - NO USE STATEMENT FILED
Tuesday, September 30, 2025NOTICE OF REVIVAL - E-MAILED
Tuesday, September 30, 2025PETITION TO REVIVE-GRANTED
Tuesday, September 30, 2025TEAS PETITION TO REVIVE RECEIVED
Tuesday, September 30, 2025SOU EXTENSION RECEIVED WITH TEAS PETITION

Related Keywords

tezzura disorders diseases preparations pharmaceutical treatment hormone replacement infectious fertility inflammatory